Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
Lucie PothenJean-Luc BalligandPublished in: Antioxidants (Basel, Switzerland) (2021)
In medicine, a legacy effect is defined as the sustained beneficial effect of a given treatment on disease outcomes, even after cessation of the intervention. Initially described in optimized control of diabetes, it was also observed in clinical trials exploring intensification strategies for other cardiovascular risk factors, such as hypertension or hypercholesterolemia. Mechanisms of legacy were particularly deciphered in diabetes, leading to the concept of metabolic memory. In a more discreet manner, other memory phenomena were also described in preclinical studies that demonstrated long-lasting deleterious effects of lipids or angiotensin II on vascular wall components. Interestingly, epigenetic changes and reactive oxygen species (ROS) appear to be common features of "memory" of the vascular wall.
Keyphrases
- cardiovascular risk factors
- cardiovascular disease
- angiotensin ii
- reactive oxygen species
- working memory
- metabolic syndrome
- type diabetes
- clinical trial
- glycemic control
- angiotensin converting enzyme
- vascular smooth muscle cells
- blood pressure
- randomized controlled trial
- cardiovascular events
- dna methylation
- gene expression
- dna damage
- cell therapy
- coronary artery disease
- skeletal muscle
- open label
- study protocol
- replacement therapy
- double blind